[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579252":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":21,"responsibleParty":97,"collaborators":10,"id":99,"slug":100,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":101,"sex":106,"minAge":107,"maxAge":10,"enrollmentInfo":108,"targetDuration":10,"studyType":111,"phases":10,"briefSummary":112,"conditions":113,"keywords":117,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Medical University Innsbruck","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Patients with MM or CLL at risk of infectious complications due to SID",null,[12,17],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Jens Lehmann, Ph.D.","CONTACT","+43 50 504 81551","jens.lehmann@i-med.ac.at",{"name":18,"role":14,"phone":19,"phoneExt":10,"email":20},"Jan-Paul Bohn, Dr.","+43 50 504 82916","jan-paul.bohn@i-med.ac.at",[22,38,53,67,83],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Medizinische Universität Innsbruck","RECRUITING","Innsbruck","Tyrolia","6020","Austria","AT",{"type":31,"coordinates":32},"Point",[33,34],11.39454,47.26266,{"lat":34,"lon":33},[37],{"name":18,"role":14,"phone":19,"phoneExt":10,"email":20},{"facility":39,"status":40,"city":41,"state":10,"zip":42,"country":28,"countryCode":29,"cosmosGeoPoint":43,"geoPoint":47,"contacts":48},"Medizinische Universität Graz","NOT_YET_RECRUITING","Graz","8010",{"type":31,"coordinates":44},[45,46],15.44197,47.06733,{"lat":46,"lon":45},[49],{"name":50,"role":14,"phone":51,"phoneExt":10,"email":52},"Katharina Prochazka, Priv.-Doz.in Dr.in med.univ.","+43 316 385 81067","k.prochazka@medunigraz.at",{"facility":54,"status":40,"city":55,"state":10,"zip":56,"country":28,"countryCode":29,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"BKH Kufstein","Kufstein","6330",{"type":31,"coordinates":58},[59,60],12.16667,47.58333,{"lat":60,"lon":59},[63],{"name":64,"role":14,"phone":65,"phoneExt":10,"email":66},"August Zabernigg, Prim. Doz. Dr.","+ 05372 6966 3001","a.zabernigg@kufnet.at",{"facility":68,"status":40,"city":69,"state":10,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Onkologischer Schwerpunkt am Oskar-Helene-Heim","Berlin","14195","Germany","DE",{"type":31,"coordinates":74},[75,76],13.41053,52.52437,{"lat":76,"lon":75},[79],{"name":80,"role":14,"phone":81,"phoneExt":10,"email":82},"Markus Schuler, Priv.-Doz. Dr. med.","+49 (0) 30 644 995 2-23","markus.schuler@onkologie-ohh.de",{"facility":84,"status":40,"city":85,"state":10,"zip":86,"country":71,"countryCode":72,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Klinikum Garmisch-Partenkirchen","Garmisch-Partenkirchen","82467",{"type":31,"coordinates":88},[89,90],11.09576,47.49209,{"lat":90,"lon":89},[93],{"name":94,"role":14,"phone":95,"phoneExt":10,"email":96},"Till Seiler, Dr. med.","+49 (0)8821 77-1520","till.seiler@klinikum-gap.de",{"type":98,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100579252","developing-a-patient-reported-outcome-pro-screening-measure-for-infections-and-measuring-quality-of-life-in-hematological-patients-with-secondary-immunodeficiency-sid-across-the-treatment-trajectory---the-pro-sid-project-100579252",false,"NCT06821880","Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project","PRO-SID","Inclusion Criteria:\n\n* Adult patient (\\>=18 years of age)\n* Access to an internet device (e.g., personal computer or tablet to use a web-based platform, or smartphone where the study app can be installed - all common iOS and Android systems)\n* German-speaking\n* Diagnosis of multiple myeloma or chronic lymphocytic leukemia\n* Secondary immunodeficiency (defined as: recurrent infections, infections requiring inpatient treatment, hypogammaglobulinemia, neutropenia and\u002For lymphopenia on differential blood cell counts, deficit in lymphocyte subsets as assessed by flow cytometry)","ALL","18 Years",{"count":109,"type":110},120,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to improve the treatment of hematological patients with secondary immunodeficiency (SID) by developing a patient-reported outcome (PRO) instrument to detect clinically diagnosed infections. The study focuses on adults diagnosed with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) who are at increased risk of infections due to SID.\n\nThe main questions it aims to answer are:\n\n1. Can a newly developed PRO screening tool for infection-related symptoms reliably detect infections in patients with SID?\n2. How does the health-related quality of life change over the treatment course\n\nParticipants will:\n\n* Complete daily electronic PRO questionnaires (ePRO) to monitor infection-related symptoms\n* Complete ePRO health-related quality of life questionnaires every 1.5 months\n* Participate in study visits every three months to ensure documentation of clinical data",[114,115,116],"Chronic Lymphocytic Leukaemia (CLL)","Multiple Myeloma (MM)","Secondary Immunodeficiency (SID)",[114,118,119,120,121,122,123],"multiple myeloma (MM)","Secondary immunodeficiency (SID)","Infection-related symptoms","Infections","PRO measure","Patient-reported outcomes","2025-02-11",{"date":126,"type":127},"2025-02-12","ACTUAL",{"date":129,"type":127},"2025-02-03",{"date":131,"type":110},"2026-07",{"name":5,"class":6},5]